Lawsuits Question Xarelto Risk While FDA Assures Public of Xarelto Clinical Trial Data

Written By:
Jessie Paluch
Jessie Paluch

Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.

This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.

TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.

Lawsuits Question Xarelto Risk While FDA Assures Public of Xarelto Clinical Trial Data

Xarelto Risk is being tested in four bellwether Xarelto case involving plaintiffs who claim the drug caused uncontrolled bleeding events moving through the courts starting in February 2017.

Xarelto bellwether trials are very important since they generally include a representative sample of all the cases filed to date.

In the Xarelto consolidated litigation, the judge selected four cases set to be tried in Louisiana, Mississippi and Texas.

lawsuits question xarelto risk blood thinner linked internal bleeding

Xarelto lawyers and the judges involved in these bellwether trials will be collecting information that will assist in determining whether groups of the Xarelto lawsuits should be settled, and if so, what might be a reasonable dollar range for these settlements.

Despite the Xarelto case moving forward, the U.S. Food and Drug Administration (FDA) recently released a statement designed to assure current and future patients of Xarelto risk.

The FDA concluded that the drug’s clinical trial results were not affected by the faulty Alere INRatio device that was recalled in July 2016.

The Alere INRatio device was used to monitor warfarin therapy in the control group of the ROCKET-AF clinical trial, which provided the main data supporting the 2011 approval of the anticoagulant drug Xarelto.

But because of concern about the functionality of the device, the FDA completed a variety of analyses to assess the impact that the device had on the study results and determined that effects on strokes or bleeding in the head were minimal.

Based on this determination, the FDA concluded Xarelto to be a safe an effective alternative to warfarin for patients with atrial fibrillation.

Table of Contents

What is Xarelto?

The U.S. Food and Drug Administration (FDA) approved Xarelto in 2011 as a more convenient alternative to Coumadin (warfarin), the traditional blood thinner that has been used since the 1950s to prevent heart attacks, strokes, and blood clots.

Although all blood thinners increase the risk of bleeding problems, Xarelto has been linked to an increased number of uncontrollable blood injuries, mostly because there is no approved antidote available for patients who use the medication, and many of the side effects have been severe because the bleeding cannot be effectively controlled.

Since Xarelto’s approval five years ago, thousands of Xarelto lawsuits have been filed against drug makers Johnson & Johnson and Bayer AG, alleging Xarelto side effects including:

  • Gastrointestinal bleeding
  • Rectal bleeding
  • Internal bleeding
  • Stroke
  • Heart attack
  • Pulmonary embolism
  • Epidural hematoma
  • Brain hemorrhages.

Some 2,800 Xarelto lawsuits have been consolidated into multidistrict litigation (MDL) in Eastern Louisiana and nearly 700 have been combined into a mass tort program in the state of Pennsylvania.

Xarelto lawyers will continue to file cases on behalf of individuals experiencing uncontrolled bleeding events while on the blood thinner while the bellwether trials move forward in February 2017.

Please share Lawsuits Question Xarelto Risk While FDA Assures Public of Xarelto Clinical Trial Data with individuals who are worried about the dangers of Xarelto.

Written By:
Jessie Paluch
Jessie Paluch

Experienced Attorney & Legal SaaS CEO

With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three.  She spent the first decade of her career working as an international tax attorney at Deloitte.

In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.

In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!

Camp Lejeune Lawsuit

Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.

Tylenol Lawsuit

Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.

AFFF Lawsuit

Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.

Do You
Have A Case?

Here, at TruLaw, we’re committed to helping victims get the justice they deserve.

Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.

Would you like our help?

Helpful Sites & Resources